Solara Active Pharma Sciences Balance Sheet Health
Financial Health criteria checks 2/6
Solara Active Pharma Sciences has a total shareholder equity of ₹14.7B and total debt of ₹9.8B, which brings its debt-to-equity ratio to 67.2%. Its total assets and total liabilities are ₹28.8B and ₹14.1B respectively.
Key information
67.2%
Debt to equity ratio
₹9.85b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹64.60m |
| Equity | ₹14.66b |
| Total liabilities | ₹14.09b |
| Total assets | ₹28.75b |
Recent financial health updates
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
May 31Recent updates
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21With EPS Growth And More, Solara Active Pharma Sciences (NSE:SOLARA) Is Interesting
Oct 28Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
May 31Need To Know: Analysts Are Much More Bullish On Solara Active Pharma Sciences Limited (NSE:SOLARA) Revenues
May 11Financial Position Analysis
Short Term Liabilities: SOLARA's short term assets (₹11.9B) exceed its short term liabilities (₹11.7B).
Long Term Liabilities: SOLARA's short term assets (₹11.9B) exceed its long term liabilities (₹2.4B).
Debt to Equity History and Analysis
Debt Level: SOLARA's net debt to equity ratio (66.7%) is considered high.
Reducing Debt: SOLARA's debt to equity ratio has increased from 61.5% to 67.2% over the past 5 years.
Debt Coverage: SOLARA's debt is not well covered by operating cash flow (15.3%).
Interest Coverage: Insufficient data to determine if SOLARA's interest payments on its debt are well covered by EBIT.